A Double-blind, Placebo-controlled, Multi-center Phase II Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral AFA-281 in Patients With Painful Lumbosacral Radiculopathy
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs AFA 281 (Primary)
- Indications Back pain; Pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors AfaSci
- 24 Oct 2024 New trial record